IDO1 and neoplasm: A central pathway involves activation of the aryl hydrocarbon receptor (AHR) by tumor-derived metabolites such as kynurenine, produced via indoleamine 2,3-dioxygenase 1 (IDO1), tryptophan 2,3-dioxygenase, or IL-4I1 [36].